Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
New words:
accessible, aggressively, answer, ascending, asserting, attention, Barr, bill, borne, breakeven, carbidopa, Catena, chose, classified, comparison, corroborated, counterparty, covenant, Department, devastating, discretion, disrupt, disruptive, dissident, economic, embedded, energy, entitledApproved, environment, erosion, FAS, female, freestanding, FSP, FSPNo, GE, geographic, GlaxoSmithKline, Hatch, Hedging, hierarchy, Ia, Ib, Jersey, Junior, Justice, lesser, levodopa, LP, male, maximize, Maximizing, merger, mitochondria, Monetizing, morphine, narrowed, NJ, overhead, peak, prejudice, proven, quoted, reassigned, reclassification, referendum, repeat, reserve, resistant, resubmit, resveratrol, Sandoz, settle, settled, slate, stake, surviving, tamper, Tang, threatening, trough, turn, unadjusted, unobservable, viii, waived, Waxman, workforce, worth
Removed:
addressed, affiliated, Alpharma, angina, announcement, branded, bringing, carryforward, Certificate, codeine, congestive, consisting, consolidated, desired, discontinuation, edema, eighteen, enhanced, epilepsy, essentially, exchanged, extension, forma, formulate, Frova, heart, hypertension, improve, injection, innovative, intensity, interval, intramuscular, jointly, largely, leadership, leverage, Lidoderm, migraine, network, notified, Nubain, occurring, opening, outline, pathway, Percocet, Percodan, permitted, pilot, plasma, precise, principle, Prism, pro, promissory, range, ranging, redeemed, reformulated, reformulating, repaid, request, revised, selecting, selectively, solution, specialist, sterile, tramadol, treated, treating, unusual, unvested, validation, wide, window
Filing tables
Filing exhibits
- 10-K Annual report
- 10.26 EX-10.26 Summary of Executive Officer Bonus Program
- 10.27 EX-10.27 Summary of the Director Compensation Program
- 10.34 EX-10.34 Form of Executive Retention Agreements
- 23 EX-23 Consent of Ernst & Young LLP
- 31 EX-31 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302
- 32 EX-32 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906
Related press release
PPCO similar filings
Filing view
External links
Exhibit 10.26
Summary of Executive Officer Bonus Program
Penwest Pharmaceuticals Co. (“the Company”) maintains a bonus program for its executive officers that is administered by the Compensation Committee (the “Committee”) of the Board of Directors of the Company. This program provides for an annual cash payout dependent on achievement by both the executive and the Company of predetermined short-term operating goals and longer-term strategic objectives. These goals also include Company goals and individual goals. Our President’s target bonus is based 100% upon achieving Company goals. Individual incentive compensation target awards are set annually by the Compensation Committee. These target awards are determined by salary grade and are subject to an adjustment based on individual performance, and typically range from 20%-40% of the executive’s salary.